HC Wainwright Predicts Scholar Rock Q3 Earnings

Scholar Rock Holding Co. (NASDAQ:SRRK) – Equities research analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Scholar Rock in a research note issued on Tuesday, November 12th. HC Wainwright analyst A. Maldonado forecasts that the company will post earnings per share of ($0.68) for the quarter. HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Scholar Rock’s current full-year earnings is ($2.37) per share. HC Wainwright also issued estimates for Scholar Rock’s Q4 2025 earnings at ($0.62) EPS.

Other equities research analysts have also recently issued research reports about the company. Wedbush reaffirmed an “outperform” rating and issued a $37.00 price target on shares of Scholar Rock in a report on Monday, November 4th. BMO Capital Markets increased their price target on Scholar Rock from $34.00 to $38.00 and gave the stock an “outperform” rating in a report on Friday, October 11th. Piper Sandler upped their target price on shares of Scholar Rock from $28.00 to $42.00 and gave the company an “overweight” rating in a research report on Tuesday, October 15th. Finally, JPMorgan Chase & Co. upped their price target on Scholar Rock from $18.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, October 14th. Six investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $34.00.

Scholar Rock Stock Up 0.4 %

SRRK opened at $27.50 on Thursday. The company has a 50-day moving average price of $20.24 and a 200 day moving average price of $13.53. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.36. The company has a market cap of $2.20 billion, a PE ratio of -11.70 and a beta of 0.47. Scholar Rock has a twelve month low of $6.76 and a twelve month high of $35.38.

Insider Activity at Scholar Rock

In other news, Director Srinivas Akkaraju sold 1,175,713 shares of Scholar Rock stock in a transaction on Monday, October 7th. The shares were sold at an average price of $29.25, for a total value of $34,389,605.25. Following the transaction, the director now directly owns 5,612,896 shares of the company’s stock, valued at $164,177,208. The trade was a 17.32 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Tracey Sacco sold 30,000 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $25.62, for a total value of $768,600.00. Following the completion of the transaction, the insider now owns 49,285 shares in the company, valued at $1,262,681.70. This trade represents a 37.84 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,413,889 shares of company stock valued at $40,652,551 over the last quarter. 19.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Scholar Rock

A number of large investors have recently modified their holdings of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Scholar Rock by 7.1% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 94,795 shares of the company’s stock valued at $759,000 after acquiring an additional 6,269 shares during the period. BNP Paribas Financial Markets boosted its position in Scholar Rock by 900.6% during the third quarter. BNP Paribas Financial Markets now owns 36,331 shares of the company’s stock worth $291,000 after purchasing an additional 32,700 shares in the last quarter. FMR LLC grew its holdings in Scholar Rock by 3.1% in the third quarter. FMR LLC now owns 10,196,046 shares of the company’s stock valued at $81,670,000 after purchasing an additional 308,813 shares during the last quarter. Fisher Asset Management LLC increased its position in shares of Scholar Rock by 593.6% in the third quarter. Fisher Asset Management LLC now owns 734,019 shares of the company’s stock valued at $5,879,000 after buying an additional 628,186 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in shares of Scholar Rock by 9.1% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 502,793 shares of the company’s stock worth $4,027,000 after buying an additional 42,139 shares during the last quarter. 91.08% of the stock is owned by hedge funds and other institutional investors.

Scholar Rock Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.